title: Cytokine-induced nitric oxide inhibits mitochondrial energy production and induces myocardial dysfunction in endotoxin-treated rat hearts.
abstract: The mechanism responsible for cardiac depression in septic shock remains unknown. The present study examined whether nitric oxide (NO) overproduced by inducible NO synthase (iNOS) can inhibit aerobic energy metabolism and impair the myocardial function in endotoxin-treated rat hearts. Lipopolysaccharide (LPS) significantly decreased systolic blood pressure (BP) to 44% of control during the 48 h treatment. Hearts from control and LPS-treated rats were perfused in a Langendorff apparatus. After LPS injection, left ventricular (LV) developed pressure (LVDP) was significantly depressed, plasma NO2-/NO3- (NO(x)) concentration was markedly increased, and myocardial adenosine 5'-triphosphate (ATP), creatine phosphate (CrP), and the ratio of ATP/adenosine 5'-diphosphate were progressively decreased with time. Immunological examination showed a significant expression of iNOS protein in the LPS-treated myocytes. Aminoguanidine, an inhibitor of iNOS, significantly attenuated these LPS-induced functional and metabolic changes. Myocardial cyclic guanosine 3',5'-monophosphate (cGMP) content was significantly increased after LPS injection. Methylene blue, an inhibitor of soluble guanylate cyclase, blunted this increase in cGMP and significantly restored the LPS-induced contractile dysfunction 6 h after LPS injection. In addition, there was a significant negative correlation between LVDP and myocardial cGMP levels as well as a significant negative correlation between LVDP and plasma NO(x) levels. In contrast, 48 h after LPS injection, methylene blue no longer affected cardiac performance, and there was a significant positive correlation between LVDP and myocardial ATP content. Furthermore, the normalized activities (as a ratio of the citrate synthase activity) of mitochondrial NADH-CoQ reductase, succinate-CoQ reductase, and ATPase, were significantly inhibited, and the swelling or disruption of mitochondria cristae was seen in the 48 h LPS treatment. These LPS-induced functional and morphological disorders in the mitochondria were significantly improved by aminoguanidine. The findings suggest that sustained production of NO by iNOS leads to contractile dysfunction via cGMP in the early stage, but that it can directly impair the mitochondrial function, lower myocardial energy production, and contribute significantly to the myocardial dysfunction in the later stage of septic shock.
authors.affiliation: Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602 8566, Japan. tatsumi@koto.kpu-m.ac.jp
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Tatsumi
authors.forename: Kazuko
authors.initials: K
authors.lastname: Akashi
authors.forename: Natsuya
authors.initials: N
authors.lastname: Keira
authors.forename: Satoaki
authors.initials: S
authors.lastname: Matoba
authors.forename: Akiko
authors.initials: A
authors.lastname: Mano
authors.forename: Jun
authors.initials: J
authors.lastname: Shiraishi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamanaka
authors.forename: Miyuki
authors.initials: M
authors.lastname: Kobara
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Hibino
authors.forename: Satoru
authors.initials: S
authors.lastname: Hosokawa
authors.forename: Jun
authors.initials: J
authors.lastname: Asayama
authors.forename: Shinji
authors.initials: S
authors.lastname: Fushiki
authors.forename: Henry
authors.initials: H
authors.lastname: Fliss
authors.forename: Masao
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Matsubara
mesh_terms: D000244:Adenosine Diphosphate / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D009202:Cardiomyopathies / Q000139:chemically induced / Q000378:metabolism* / Q000473:pathology; D016207:Cytokines / Q000378:metabolism*; D004734:Energy Metabolism / Q000187:drug effects*; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000008:administration & dosage*; D008297:Male; D008929:Mitochondria, Heart / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology / Q000648:ultrastructure; D009569:Nitric Oxide / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D052247:Nitric Oxide Synthase Type II; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D016207:Cytokines; D008070:Lipopolysaccharides; D009569:Nitric Oxide; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat